BioAtla secured FDA alignment on the design of its Phase 3 registrational study for ozuriftamab vedotin, a ROR2-targeting ADC,...

NRx Pharmaceuticals has refiled its ANDA for KETAFREE, a preservative-free ketamine injection, and reports supportive FDA correspondence pointing to...

Inotiv posted preliminary Q4 FY2025 revenue of $137.5–138.5 million and full-year FY2025 revenue of $512.5–513.5 million, alongside a Discovery...

Cosmos Health posted record third-quarter results, with revenue up 38% year over year to $17.1 million, gross profit more...

INVO Fertility reported third-quarter 2025 revenue of $1.76 million, up 23% year over year, with consolidated clinic revenue from...

Genfit reported third-quarter 2025 financials with cash and equivalents at €119.0 million and nine-month revenue of €39.2 million, driven...

Nanobiotix has closed a non-dilutive royalty financing with HealthCare Royalty worth up to $71 million, delivering a $50 million...

Ocular Therapeutix has granted inducement equity awards to eight newly hired non-executive employees under its 2019 inducement stock incentive...

Novo Nordisk has closed its acquisition of Akero Therapeutics for $54 per share in cash, valuing the deal at...

Japan’s Ministry of Health, Labour and Welfare has approved Dupixent (dupilumab) for children aged 6 to 11 with severe...